Duality Advisers LP Takes Position in InMode Ltd. (NASDAQ:INMD)

Duality Advisers LP purchased a new stake in InMode Ltd. (NASDAQ:INMD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 79,714 shares of the healthcare company's stock, valued at approximately $1,773,000. Duality Advisers LP owned about 0.10% of InMode as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Exchange Traded Concepts LLC acquired a new stake in InMode during the third quarter valued at approximately $27,000. Carmel Capital Partners LLC acquired a new stake in InMode during the third quarter valued at approximately $36,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of InMode during the 3rd quarter worth approximately $40,000. Sunbelt Securities Inc. acquired a new stake in shares of InMode during the 3rd quarter worth approximately $47,000. Finally, CWM LLC raised its position in shares of InMode by 38.3% during the 4th quarter. CWM LLC now owns 2,454 shares of the healthcare company's stock worth $55,000 after purchasing an additional 680 shares during the period. Hedge funds and other institutional investors own 68.04% of the company's stock.

InMode Trading Up 1.3 %

INMD traded up $0.23 during trading hours on Tuesday, hitting $17.37. The company's stock had a trading volume of 923,523 shares, compared to its average volume of 1,590,664. InMode Ltd. has a fifty-two week low of $16.96 and a fifty-two week high of $48.25. The firm has a market capitalization of $1.46 billion, a PE ratio of 7.55 and a beta of 2.16. The company has a 50-day simple moving average of $20.68 and a 200 day simple moving average of $21.72.

InMode (NASDAQ:INMD - Get Free Report) last posted its earnings results on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. InMode had a return on equity of 29.80% and a net margin of 40.22%. The firm had revenue of $126.80 million for the quarter, compared to analysts' expectations of $124.77 million. During the same period last year, the firm earned $0.69 EPS. The firm's revenue was down 5.1% compared to the same quarter last year. Research analysts expect that InMode Ltd. will post 2.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on INMD shares. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research report on Tuesday, April 9th. Barclays dropped their price target on InMode from $34.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, April 12th. Finally, UBS Group increased their price target on InMode from $24.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 14th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $32.80.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.